Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients | Your Money


SEATTLE–(BUSINESS WIRE)–Nov 29, 2021–

Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases, has selected AWS as its preferred cloud provider. Innovating on AWS and with the help of AWS experts and partners in healthcare and life sciences, Gilead provides its data scientists with the latest advances in machine learning and analytics. These capabilities fuel data-driven decision making across the organization—from biomarker discovery through manufacturing and clinical trial recruitment—and deliver insights that can help Gilead refine its drug pipeline. The company also relies on AWS to host all workloads for its enterprise resource planning (ERP) transformation project to implement SAP S/4HANA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005047/en/

“With AWS as our preferred cloud provider, our researchers can use AWS’s portfolio of services to gain the insights, agility, and security needed to deliver new medicines at speed, and treat the individual according to their unique needs, not just the disease,” said Marc Berson, Senior Vice President and Chief Information Officer at Gilead. “AWS’s performance, infrastructure, and scale are the foundations on which we will complete our ERP transformation and become a more efficient, agile, secure, and data-driven business in the cloud.”

Gilead is reimagining its bioinformatics compute infrastructure in the world’s leading cloud. The use of AWS’s compute, machine learning, and database capabilities will support the analysis and integration of diverse genomics, imaging, and experimental datasets to support breakthroughs in how Gilead diagnoses and treats diseases. For instance, by securely analyzing deidentified patient genomic data at scale on AWS to reveal patterns, Gilead can uncover insights on how people living with cancer respond to existing therapeutic options, potentially accelerating the discovery of new…

Source…